FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Symons Julian A.
  2. Issuer Name and Ticker or Trading Symbol
Aligos Therapeutics, Inc. [ALGS] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
See Remarks
(Last)
(First)
(Middle)
C/O ALIGOS THERAPEUTICS, INC., ONE CORPORATE DRIVE, 2ND FLOOR		 3. Date of Earliest Transaction (Month/Day/Year)
02/27/2024
(Street)

SOUTH SAN FRANCISCO, CA 94080		 4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $ 16.18 02/27/2024   D     200,000 01/01/2021 12/01/2030 Common Stock 200,000 $ 0 (1) 0 D  
Stock Option (Right to Buy) $ 3.06 02/27/2024   D     105,000 03/04/2022 02/04/2032 Common Stock 105,000 $ 0 (2) 0 D  
Stock Option (Right to Buy) $ 3.06 02/27/2024   D     26,250 02/04/2025 02/04/2032 Common Stock 26,250 $ 0 (3) 0 D  
Stock Option (Right to Buy) $ 0.96 02/28/2024   A   58,822     (4) 12/01/2030 Common Stock 58,822 $ 0 (1) 58,822 D  
Stock Option (Right to Buy) $ 0.96 02/28/2024   A   74,998     (5) 02/04/2032 Common Stock 74,998 $ 0 (2) 74,998 D  
Stock Option (Right to Buy) $ 0.96 02/28/2024   A   18,750     (4) 02/04/2032 Common Stock 18,750 $ 0 (3) 18,750 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Symons Julian A.
C/O ALIGOS THERAPEUTICS, INC.
ONE CORPORATE DRIVE, 2ND FLOOR
SOUTH SAN FRANCISCO, CA 94080		       See Remarks  

Signatures

 /s/ Lesley Ann Calhoun, as attorney-in fact for Julian A. Symons   02/28/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 200,000 of the issuer's shares granted to the reporting person on December 1, 2020. In exchange, on February 28, 2024, the reporting person received a replacement option, for 58,822 shares, having an exercise price of $0.96 per share.
(2) On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 105,000 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 74,998 shares, having an exercise price of $0.96 per share.
(3) On February 27, 2024, the issuer canceled, pursuant to the issuer's option exchange program, an option for 26,250 of the issuer's shares granted to the reporting person on February 4, 2022. In exchange, on February 28, 2024, the reporting person received a replacement option, for 18,750 shares, having an exercise price of $0.96 per share.
(4) The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary.
(5) The shares subject to the option will vest and become exercisable as to 75% of the total number of shares subject to the option on the one year anniversary of the date of the grant and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued service with the issuer on each such vesting date.
 
Remarks:
Executive Vice President, Chief Scientific Officer

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.